ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called ACY-1215 in combination with ibrutinib or
idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocyic Leukemia
(CLL).